地拉罗司治疗铁质积聚疗效怎么样呢？

Iron overload refers to a pathological phenomenon in which excessive iron is deposited in human tissues and organs, leading to cell damage and organ dysfunction. Iron overload can cause damage to cardiovascular, endocrine, liver, kidney, nervous system, etc., leading to various diseases and serious harm. Iron chelators can effectively increase the excretion of iron, reduce the iron content in the body and its pathological deposition in various organs. They are currently the only effective drugs for the treatment of iron overload. So, how effective is deferasirox in treating iron accumulation?

Therapeutic effects of deferasirox in treating iron accumulation:

Analysis of the effectiveness of deferasirox and deferoxamine in the treatment of iron overload in transfusion-dependent thalassemia:

Objective: To compare the effects of deferasirox and deferoxamine in the treatment of transfusion-dependent thalassemia (TDT), and to evaluate the advantages and limitations of monotherapy.

Methods: The case data of TDT combined with iron overload and treated with deferasirox or deferoxamine from January 2013 to June 2015 were retrospectively analyzed. Fifty-eight children in the deferasirox group were treated with deferasirox 20-35 mg/(kg·d), and 27 children in the deferoxamine group were treated with deferoxamine 25-45 mg/(kg·d), 5 days a week. The patients were followed up for 1 year since taking the medication, and serum ferritin (SF) levels, liver and kidney functions, and blood routine were measured every 3 to 6 months.

Results: There was no statistically significant difference in the median age, average iron intake rate and pre-treatment SF between the two groups of children.

After 6 months of follow-up, the mean SF decreases in the deferasirox group and deferoxamine group were 168 (-2 650, 7 254) ng/mL and 170 (-260, 599) ng/mL respectively (P0.05). The decrease in SF in the deferasirox group was positively correlated with dose (P<0.05). After 7 to 12 months of follow-up, the mean SF reduction values ​​in the deferasirox group and deferoxamine group were 212 (-370, 795) ng/mL and -1 330 (-2 454, -206) ng/mL respectively (P0.05).

Conclusion: It has advantages over deferoxamine in the treatment of TDT, and the maximum dose within the tolerance range should be used. Deferasirox can stabilize SF and should be used long-term. A safe dose of deferoxamine is not effective in children with massive blood transfusions.